New insights in toxic epidermal necrolysis (lyells syndrome): Clinical considerations, pathobiology and targeted treatments revisited

Drug Safety

Volumn 33, Issue 3, 2010, Pages 189-212

  Paquet, Philippe ^a   Piérard, Gérald E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ANTIINFECTIVE AGENT; CARBAMAZEPINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; FAS ANTIGEN; GLUTATHIONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1; ISOXICAM; LAMOTRIGINE; NEVIRAPINE; OXYPHENBUTAZONE; PANTOPRAZOLE; PENTOXIFYLLINE; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; PIROXICAM; SERTRALINE; TRAMADOL; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CONSERVATIVE TREATMENT; CORTICOSTEROID THERAPY; DEBRIDEMENT; DIFFERENTIAL DIAGNOSIS; DRESS SYNDROME; ERYTHEMA MULTIFORME; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KERATINOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MORTALITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLASMAPHERESIS; PREDICTION; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEVENS JOHNSON SYNDROME; SYNDROME DELINEATION; TOXIC EPIDERMAL NECROLYSIS;

ACETYLCYSTEINE; APOPTOSIS; DRUG ERUPTIONS; EPIDERMAL NECROLYSIS, TOXIC; EPIDERMIS; ERYTHEMA MULTIFORME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KERATINOCYTES; LYMPHOCYTE ACTIVATION; NECROSIS; SKIN; STEVENS-JOHNSON SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 76949107229     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11532540-000000000-00000     Document Type: Review

References (290)

1. Revuz J. Alan Lyell and Lyell's syndrome. J Eur Acad Dermatol Venereol 2008; 22: 1001-1002
2. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epi-dermal necrolysis (Lyell syndrome): incidence and drug etiology in France. Arch Dermatol 1990; 126: 37-42
3. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 1990; 126: 43-47
4. Schopf E, Stuhmer A, Rzany B, et al. Toxic epidermal ne-crolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991; 127: 839-842
5. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49: 769-773
6. Revuz J, Penso D, Guillaume JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160-1165
7. Parsells-Kelly J, Auquier A, Rzany B, et al. An inter-national collaborative case-control study of severe cutaneous adverse reactions (SCAR): design and methods. J Clin Epidemiol 1995; 45: 1099-1108
8. Gravante G, Esposito G, Montone A, et al. More than two different bacterial species isolated from blood of toxic epidermal necrolysis patients significantly increase mortality. Burns 2006; 32: 793-794
9. Halebian P, Corder V, Madden M, et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-512
10. Jin H, Qiao J, Wang B, et al. Toxic epidermal necrolysis complicated by Mucor infection. Int J Dermatol 2008; 47: 383-386
11. Prendiville J. Stevens-Johnson syndrome and toxic epidermal necrolysis. Adv Dermatol 2002; 18: 151-173
12. Schulz JT, Sheridan RL, Ryan CM, et al. A 10-year ex-perience with toxic epidermal necrolysis. J Burn Care Rehabil 2000; 21: 199-204
13. Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000; 1: 349-360
14. Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necro-lysis in children: a review of 10 years' experience. Drug Saf 2002; 25: 965-972
15. Khalili B, Bahna S. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 2006; 97: 272-281
16. Pereira F, Mudgil AV, Rosmarin D. Toxic epidermal ne-crolysis. J Am Acad Dermatol 2007; 56: 181-200
17. Abood G, Nickoloff BJ, Gamelli RL. Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? J Burn Care Res 2008; 29: 269-276
18. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993; 129: 92-96
19. Wolf R, Wolf D, Davidovici B. In the pursuit of classifying severe cutaneous adverse reactions. Clin Dermatol 2007; 25: 348-349
20. Roujeau JC. Stevens-Johnson syndrome and toxic epi-dermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997; 24: 726-728
21. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Cor-relations between clinical patterns and causes of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol 2002; 138: 1019-1024
22. Schalock P, Dinulos JG, Pace N, et al. Erythema multi-forme due to Mycoplasma pneumonia infection in two children. Ped Dermatol 2006; 23: 546-555
23. Lam NS, Yang YH, Wang LC, et al. Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children. J Microbiol Immunol Infect 2004; 37: 266-270
24. Rzany B, Hering O, Mockenhaupt M, et al. Histopatho-logical and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996; 135: 6-11 (Pubitemid 26225106)
25. Paquet P, Nikkels A, Arrese J, et al. Macrophages and tu-mor necrosis factor a in toxic epidermal necrolysis. Arch Dermatol 1994; 130: 605-608
26. Paquet P, Paquet F, Al Saleh W, et al. Immunoregulatory effectors in drug-induced toxic epidermal necrolysis. Am J Dermatopathol 2000; 22: 413-417
27. Quaglino P, Caproni M, Osella-Abate S, et al. Serum in-terleukin-13 levels are increased in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis but not in those with erythema multiforme. Br J Dermatol 2008; 158: 184-186
28. Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmon-ary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997; 23: 1237-1244
29. Wallis C, McClymont W. Toxic epidermal necrolysis with adult respiratory distress syndrome. Anaesthesia 1995; 50: 801-803
30. Roujeau JC. Toxic epidermal necrolysis (Lyell syndrome): more than "acute skin failure". Intensive Care Med 1992; 18: 4-5
31. Chosidow O, Delchier JC, Chaumette MT, et al. Intestinal involvement in drug-induced toxic epidermal necrolysis [letter]. Lancet 1991; 337: 928
32. Michel P, Joly P, Ducrotte P, et al. Ileal involvement in toxic epidermal necrolysis (Lyell syndrome). Dig Dis Sci 1993; 38: 1938-1941
33. Sakai N, Yoshizawa Y, Amano A, et al. Toxic epidermal necrolysis complicated by multiple intestinal ulcers. Int J Dermatol 2008; 47: 180-182
34. Blum L, Chosidow O, Rostoker G, et al. Renal involve-ment in toxic epidermal necrolysis. J Am Acad Dermatol 1996; 34: 1088-1090
35. Coetzer M, van der Merwe AE, Warren BL. Toxic epi-dermal necrolysis in a burn patient complicated by acute pancreatitis. Burns 1998; 24: 181-183
36. Kvasnicka J, Rezac J, Svejda J, et al. Disseminated in-travascular coagulation associated with toxic epidermal necrolysis (Lyell's syndrome). Br J Dermatol 1979; 100: 551-558
37. Roujeau JC, Moritz S, Guillaume JC, et al. Lymphopenia and abnormal balance of T lymphocyte subpopulations in toxic epidermal necrolysis. Arch Dermatol Res 1985; 277: 23-27
38. Goens J, Song M, Fondu P, et al. Haematological dis-turbances and immune mechanisms in toxic epidermal necrolysis. Br J Dermatol 1986; 114: 255-259
39. Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2004; 4: 561-572
40. Takeda H, Mitsuhashi Y, Kondo S, et al. Toxic epidermal necrolysis possibly linked to hyperacute graft-versus-host disease after allogeneic bone marrow transplantation. J Dermatol 1987; 24: 635-641
41. Villada G, Roujeau JC, Cordonnier C, et al. Toxic epi-dermal necrolysis after bone marrow transplantation: study of nine cases. J Am Acad Dermatol 1990; 23: 870-875
42. Stone N, Scheerin S, Burge S. Toxic epidermal necrolysis and graft vs host disease: a clinical spectrum but a diagnostic dilemma. Clin Exp Dermatol 1999; 24: 260-262
43. Paquet P, Arrese JE, Beguin Y, et al. Clinicopathological differential diagnosis of drug-induced toxic epidermal necrolysis (Lyell's syndrome) and acute graft-versus-host reaction. Curr Top Pathol 2001; 94: 49-63
44. Whitaker-Menezes D, Jones SC, Friedman TM, et al. An epithelial target site in experimental graft-versus-host disease and cytokine-mediated cytotoxicity is defined by cytokeratin 15 expression. Biol Blood Marrow Transplant 2003; 9: 559-570
45. Zhan Q, Signoretti S, Whitaker-Menezes D, et al. Cyto-keratin-15-positive basal epithelial cell targeted in graft-versus-host disease express a constitutive antiapoptotic phenotype. J Invest Dermatol 2007; 127: 106-115
46. Paquet P, Pierard GE. Differential pathomechanisms of epidermal necrolytic blistering diseases. Int J Mol Med 2002; 10: 695-699
47. Sidoroff A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern. J Cutan Pathol 2001; 28: 113-119 (Pubitemid 32112994)
48. Britschgi M, Steiner UC, Schmid S, et al. T-cell involve-ment in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001; 107: 1433-1441
49. Schmid S, Kuechler PC, Britschgi M, et al. Acute general-ized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol 2002; 161: 2079-2086
50. Vittorio C, Muglia J. Anticonvulsant hypersensitivity syn-drome. Arch Intern Med 1995; 155: 2285-2290
51. Sullivan JR, Shear NH. The drug hypersensitivity syn-drome: what is the pathogenesis? Arch Dermatol 2001; 137: 357-364
52. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-1607
53. Mockenhaupt M, Kelly JP, Kaufman D, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necro-lysis associated with non steroidal anti-inflammatory drugs: a multinational perspective. J Rheumatol 2003; 30: 2234-2240
54. Mockenhaupt M, Messenheimer J, Tennis P, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necro-lysis in new users of anti-epileptics. Neurology 2005; 64: 1134-1138
55. La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective Cox-2 inhibitors. Drug Saf 2005; 28: 917-924
56. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32
57. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Derma-tol 2008; 128: 35-44
58. Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of anti-epileptic therapy: a case-control study. Lancet 1999; 353: 2190-2194
59. Picard E, Gillis D, Klapholz L, et al. Toxic epidermal ne-crolysis associated with Klebsiella pneumoniae sepsis. Ped Dermatol 1994; 11: 331-334
60. Fournier S, Bastuji-Garin S, Mentec H, et al. Toxic epi-dermal necrolysis associated with Mycoplasma pneumo-niae infection. Eur J Clin Microbiol Infect Dis 1995; 14: 558-559
61. Pedrazzoli P, Rosti V, Rossi R, et al. Toxic epidermal ne-crolysis following Yersinia enterocolitica infection [letter]. Int J Dermatol 1993; 32: 75
62. Dobrosavljevic D, Milinkovic M, Nikolic M. Toxic epi-dermal necrolysis following morbilli-parotitis-rubella vaccination. J Eur Acad Dermatol Venereol 1999; 13: 59-61
63. Ball R, Ball L, Wise R, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Ped Infect Dis J 2001; 20: 219-223
64. Friedman HZ, Acias AM, Catchatourian R, et al. Toxic epidermal necrolysis following bone marrow transplantation. Cutis 1984; 34: 158-166
65. Hilgendorf I, Casper J, Sviland L, et al. Toxic epidermal necrolysis after allogenic haematopoietic stem cell transplantation. Bone Marrow Transpl 2007; 39: 245-246
66. Arvidson J, Kildal M, Linde T, et al. Toxic epidermal ne-crolysis and haemolytic uremic syndrome after allogeneic stem-cell transplantation. Pediatr Transplant 2007; 11: 689-693
67. Jongen-Lavrencic M, Schneeberger PM, van der Hoeven JG. Ciprofloxacin-induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus. Infection 2003; 6: 428-429
68. Horne NS, Narayan A, Young RM, et al. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev 2006; 5: 160-164
69. Aguiar D, Pazo R, Duran I, et al. Toxic epidermal necro-lysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neur Oncol 2004; 66: 345-350
70. Gravante G, Delogu D, Esposito G, et al. Toxic epidermal necrolysis in oncologic patients. Am J Clin Dermatol 2006; 7: 397-398 (Pubitemid 46998576)
71. Marque M, Girard C, Besses D, et al. Maladie de Hodgkin a debut aigu au decours d'un syndrome de Lyell. Ann Dermatol Venereol 2007; 134: 767-770
72. Saiag P, Caumes E, Chosidow O, et al. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992; 26: 567-574
73. Rzany B, Mockenhaupt M, Stocker U, et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necro-lysis in patients with the acquired immunodeficiency syndrome in Germany [letter]. Arch Dermatol 1993; 129: 1059
74. Correia O, Delgado L, Santos C, et al. HIV-1 in blister fluid of a patient with toxic epidermal necrolysis and AIDS. Lancet 1994; 344: 1432-1433
75. Acheampong E, Parveen Z, Muthoga L, et al. Molecular interactions of human immunodeficiency virus type 1 with primary human oral keratinocytes. J Virol 2005; 79: 8440-8453
76. Caumes E, Bossi P, Katlama C, et al. Toxidermies dues aux antiretroviraux chez les patients infectes par le VIH. Presse Med 2003; 32 (28): 1325-1333
77. Rotunda A, Hirsch R, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 2003; 83: 1-9
78. Yeung CK, Ma SY, Hon C, et al. Aetiology in sixteen cases of toxic epidermal necrolysis and Stevens-Johnson syndrome admitted within eight months in a teaching hospital. Acta Derm Venereol 2003; 83: 179-182
79. Ducic I, Shalom A, Rising W, et al. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg 2002; 110: 768-773
80. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-153
81. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126: 272-276
82. Trent JT, Kirsner RS, Romanelli P, et al. Analysis of in-travenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN. Arch Dermatol 2003; 139: 39-43
83. Kim K, Lee DP, Suh HS, et al. Toxic epidermal necrolysis: analysis of clinical course and Scorten-based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol 2005; 85: 497-502
84. Cartotto R, Mayich M, Nickerson D, et al. SCORTEN accurately predicts mortality among toxic epidermal ne-crolysis patients treated in a burn center. J Burn Care Res 2008; 29: 141-146
85. Imahara S, Holmes JH, Heimbach DM, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res 2006; 27: 270-275
86. Hague JS, Goulding JMR, Long TMW, et al. Respiratory involvement in toxic epidermal necrolysis portends a poor prognosis that may not be reflected in SCORTEN. Br J Dermatol 2007; 157: 1294-1296
87. Vocishampayan SS, Das AL, Verma R. SCORTEN: does it need modification? Ind J Dermatol Venereol Leprol 2008; 74: 35-37
88. Quinn A, Brown K, Bonish B, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol 2005; 141: 683-687
89. Faye O, Wechsler J, Roujeau CJ. Cell-mediated im-munologic mechanism and severity of TEN. Arch Dermatol 2005; 141: 775-776
90. Claessens N, Delbeke L, Lambert J, et al. Toxic epidermal necrolysis associated with treatment for preterm labor. Dermatology 1998; 196: 461-462
91. Pacheco H, Araujo T, Kerdel F. Toxic epidermal necrolysis in a pregnant, HIV-infected woman. Int J Dermatol 2002; 41: 600-601
92. Rodriguez G, Trent J, Mirzabeigi M, et al. Toxic epidermal necrolysis in a mother and fetus. J Am Acad Dermatol 2006; 55: S96-8
93. Gibson C, Poduri KR. Heterotopic ossification as a com-plication of toxic epidermal necrolysis. Arch Phys Med Rehabil 1997; 78: 774-776
94. Samanci N, Balci N, Alpsoy E. Heterotopic ossification related to toxic epidermal necrolysis in a patient with Behçet's disease. J Dermatol 2005; 32: 469-473
95. McIvor RA, Zaidi J, Peters WJ, et al. Acute and chronic respiratory complications of toxic epidermal necrolysis. J Burn Care Rehabil 1996; 17: 237-240
96. Kamada N, Kinoshita K, Togawa Y, et al. Chronic pul-monary complications associated with toxic epidermal necrolysis: report of a severe case with anti-RO/SS-A and a review of the published work. J Dermatol 2006; 33: 616-622
97. Spies M, Sanford AP, Aili Low JF, et al. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics 2001; 108: 1162-1168
98. Sheridan RL, Schulz J, Ryan C, et al. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics 2002; 109: 74-78
99. Magina S, Lisboa C, Leal V, et al. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology 2003; 207: 33-36
100. Paquet P, Pierard GE. Intense pulsed light treatment of persistent facial hypermelanosis following drug-induced toxic epidermal necrolysis. Dermatol Surg 2004; 30: 1522-1525
101. Haber J, Hopman W, Gomez M, et al. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil 2005; 26: 33-41
102. Oplatek A, Brown K, Sen S, et al. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 2006; 1: 26-33
103. Paquet P, Jacob E, Quatresooz P, et al. Delayed re-epithelialization and scarring deregulation following drug-induced toxic epidermal necrolysis. Burns 2007; 33: 100-104
104. Kavanagh GM, Page P, Hanna MM. Silicone gel treatment of extensive hypertrophic scarring following toxic epidermal necrolysis. Br J Dermatol 1994; 130: 540-541
105. Paquet P, Arrese JE, Greimers R, et al. Eruptive speckled melanocytic naevi following drug-induced toxic epidermal necrolysis. Eur J Dermatol 1995; 5: 379-382
106. Garcia-Doval I, Florez A, De La Torre C, et al. Transient verrucous hyperplasia after toxic epidermal necrolysis. Br J Dermatol 2003; 149: 1082-1083
107. Di Pascuale M, Espana E, Tzong-Shyue Liu D, et al. Correlation of corneal complications with eyelid cica-tricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology 2005; 112: 904-912
108. Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy 2007; 62: 527-531
109. Chang YS, Huang FC, Tseng SH, et al. Erythema multi-forme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Cornea 2007; 26: 123-129
110. De Rojas V, Dart JK, Saw V. The natural history of Stevens-Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol 2007; 91: 1048-1053
111. Sibaud V, Fricain JC, Leaute-Labreze C, et al. Ulcerations muqueuses persistantes: une complication rare de necro-lyse epidermique toxique. Ann Dermatol Venereol 2005; 132: 682-685
112. Sedghizadeh PP, Kumar SK, Gorur A, et al. Toxic epi-dermal necrolysis with a rare long-term oral complication requiring surgical intervention. Oral Surg Oral Med Oral Pathol Oral Radiol Endodentics 2008; 105: 229-233
113. Roujeau JC, Philippoteau C, Koso M, et al. Sjogren-like syndrome after drug-induced toxic epidermal necrolysis. Lancet 1985; I: 609-611 (Pubitemid 15139740)
114. Paquet P, Jacob E, Pierard GE. Cystic lesion of the parotid following drug-induced toxic epidermal necrolysis (Lyell's syndrome). J Oral Pathol Med 2005; 34: 380-382 (Pubitemid 40868411)
115. Barrera JE, Meyers A, Hartford EC. Hypopharyngeal stenosis and dysphagia complicating toxic epidermal necrolysis. Arch Otolaryngol Head Neck Surg 1998; 124: 1375-1376
116. Clayton N, Kennedy P. Management of dysphagia in toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS). Dysphagia 2007; 22: 187-192
117. Noel JC, Buxant F, Fayt I, et al. Vulval adenosis associated with toxic epidermal necrolysis. Br J Dermatol 2005; 153: 457-458
118. Meneux E, Wolkenstein P, Haddad B, et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol 1998; 91: 283-287
119. Merot Y, Saurat JH. Clues to pathogenesis of toxic epi-dermal necrolysis. Int J Dermatol 1985; 24: 165-168
120. Paquet P, Quatresooz P, Pierard GE. Factor XIIIa-positive dendrocytes in drug-induced toxic epidermal necrolysis (Lyell's syndrome): paradoxical activation in skin and rarefaction in lymph nodes. Dermatology 2003; 206: 374-378
121. Roujeau JC, Dubertret L, Moritz S, et al. Involvement of macrophages in the pathology of toxic epidermal necro-lysis. Br J Dermatol 1985; 113: 425-430
122. Villada G, Roujeau JC, Clerici T, et al. Immunopathology of toxic epidermal necrolysis. Arch Dermatol 1992; 128: 50-53
123. Bachot N, Roujeau JC. Physiopathology and treatment of severe drug eruption. Curr Opin Allergy Clin Immunol 2001; 1: 293-298
124. Reilly T, Lash L, Doll MA, et al. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000; 114: 1164-1173
125. Baron J, Merk HF. Drug metabolism in the skin. Curr Opin Allergy Clin Immunol 2001; 1: 287-291
126. Wolkenstein P, Chanthavy T, Lecoeur S, et al. Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. Chem Biol Inter 1998; 113: 39-50
127. Vyas P, Roychowdhury S, Koukouritaki S, et al. Enzyme-mediated protein haptenation of dapsone and sulfa-methoxazole in human keratinocytes: expression and role of flavin-containing monooxygenases and peroxidases. J Pharmacol Exp Ther 2006; 319: 497-505 (Pubitemid 44455157)
128. Wolkenstein P, Carriere V, Charue D, et al. A slow acetyl-ator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5: 255-258
129. Dietrich A, Kawakubo Y, Rzany B, et al. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol 1995; 4: 313-316
130. Paquet P, Pierard GE. Keratinocyte injury in drug-induced toxic epidermal necrolysis: simultaneous but distinct topographic expression of CD95R and calprotectin. Int J Mol Med 2002; 10: 145-147
131. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necro-lysis. J Invest Dermatol 2004; 123: 850-855
132. Caproni M, Torchia D, Schingaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006; 155: 722-728 (Pubitemid 44352552)
133. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 162: 1515-1520
134. Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal ne-crolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003; 162: 1515-1520
135. Marzano AV, Frezzolini A, Caproni M, et al. Immuno-histochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunopathol Pharmacol 2007; 20: 557-566
136. Paquet P, Jacob E, Damas P, et al. Analytical quantifica-tion of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res 2005; 297: 266-273
137. Tapia B, Padial A, Sanchez-Sabate E, et al. Involvement of CCL 27-CCR 10 interactions in drug-induced cutaneous reactions. J Allergy Clin Immunol 2004; 114: 335-340
138. Paquet P, Ribbens C, Pierard GE. Epidermal interleukin-8 and its receptor CXCR2 in drug-induced toxic epidermal necrolysis. Clin Exp Dermatol 2007; 32: 728-732 (Pubitemid 47609743)
139. Posadas SJ, Torres MJ, Mayorga C, et al. Gene expression levels of cytokine profile and cytotoxic markers in non immediate reactions to drugs. Blood Cells Mol Dis 2002; 29: 179-189
140. Friedmann PS, Strickland I, Pirmohamed M, et al. In-vestigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994; 130: 598-604
141. Paquet P, Pierard GE. Epidermal calprotectin in drug-induced toxic epidermal necrolysis. J Cutan Pathol 1999; 26: 301-305
142. Paquet P, Jacob E, Pirson J, et al. Drug-induced toxic epi-dermal necrolysis and pancytopenia: a puzzling association. Int J Mol Med 2005; 16: 29-33
143. Blacker KL, Olsen E, Vessey DA, et al. Characterization of gluthatione S-transferase in cultured human keratino-cytes. J Invest Dermatol 1991; 97: 442-446
144. Moral A, Palou J, Lafuente A, et al. Immunohistochemical study of a, m and p class glutathione S-transferase expression in malignant melanoma. Br J Dermatol 1997; 136: 345-350
145. Paquet P, Pierard GE. Glutathione-S-transferase p expres-sion in toxic epidermal necrolysis: a marker of putative oxidative stress in keratinocytes. Skin Pharmacol Physiol 2007; 20: 66-70
146. Hayes J, Pulford D. The glutathione S-transferase super-gene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445-600
147. Schreck R, Baeuerle P. A role for oxygen radicals as second messengers. Trends Cell Biol 1991; 1: 39-42
148. Schreck R, Albermann KAJ, Baeuerle P. Nuclear factor Kb: an oxidative stress-responsive transcription factor of eu-karyotic cells (areview). Free Rad Res Com 1992; 17: 221-237
149. Safarian T, Bredesen D. Is apoptosis mediated by reactive oxygen species? Free Rad Res 1994; 21: 1-8
150. Lange RW, Hayden PJ, Chignell CF, et al. Anthralin stimulates keratinocyte-derived proinflammatory cyto-kines via generation of reactive oxygen species. Inflam Res 1998; 47: 174-181
151. Halliwell B. Free radicals and antioxidants: a personal view. Nutr Rev 1994; 52: 253-265
152. Staal FJT, Ela SW, Rodenrer M, et al. Glutathione defi-ciency and human immunodeficiency virus infection. Lancet 1992; 339: 909-912
153. Herzenberg LA, Rosa SCD, Dubs JE. Glutathione defi-ciency is associated with compound survival in HIV diseases. Proc Nat Acad Sci 1997; 94: 1967-1972
154. Weltzien HU, Marlon C, Martin S, et al. T cell immune response to haptens: structural models for allergic and autoimmune reactions. Toxicology 1996; 107: 141-151
155. Griem P, Walferink M, Sacha B, et al. Allergic and auto-immune reactions to xenobiotics: how do they arise? Immunol Today 1998; 19: 133-141
156. Roychowdhury S, Vyas P, Reilly T, et al. Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes. J Pharmacol Exp Ther 2005; 314: 43-52
157. Pichler WJ. Pharmacological interaction of drugs with an-tigen-specific immune receptor: the p-i concept. Curr Opin Allergy Clin Immunol 2002; 2: 301-305
158. Gerber BO, Pichler WJ. Noncovalent interactions of drugs with immune receptors may mediate drug-induced hyper-sensitivity reactions. AAPS J 2006; 8: E160-5
159. Yang C, Hung S, Juo C, et al. HLA-B* 1502-bound peptides: implications for the pathogenesis of carbama-zepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2007; 120: 870-877
160. Chung WH, Hung SL, Chen YS. Human leukocyte anti-gens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007; 7: 317-323
161. Roujeau JC, Nhan Huynh T, Bracq C, et al. Genetic sus-ceptibility of toxic epidermal necrolysis. Arch Dermatol 1987; 123: 1171-1173
162. Chung WH, Hung S, Hong HS, et al. A marker for Stevens-Johnson syndrome [letter]. Nature 2004; 428: 486
163. Hung SL, Chung WH, Ju SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genom 2006; 16: 297-307
164. Hung SI, Chung WH, Lian LB, et al. HLA-B* 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134-4139
165. Ueta M, Sotozono C, Tokanaga K, et al. Strong associa-tion between HLA-A* 0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol 2007; 143: 367-368
166. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome y: ethnicity matters. Pharmaco-genomics J 2006; 6: 265-268
167. Pirmohamed M, Arbuckle J, Bowman C, et al. Investiga-tion into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2007; 8: 1661-1691
168. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenetics Genomics 2008; 18: 99-107
169. Ueta M, Tokunaga K, Sotozono C, et al. HLA class I and II gene polymorphism in Stevens-Johnson syndrome with ocular complications in Japanese. Mol Vision 2008; 14: 550-555
170. Dainichi T, Uchi H, Moroi Y, et al. Stevens-Johnson syn-drome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology 2007; 215: 86-88
171. Ueta M, Sotozono C, Inatomi T, et al. Toll-like receptor 3 gene polymorphism in Japanese patients with Stevens-Johnson syndrome. Br J Ophthalmol 2007; 91: 962-965
172. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a me-chanism of keratinocyte death in toxic epidermal necro-lysis. Br J Dermatol 1996; 134: 710-714
173. Paquet P, Pierard GE. Toxic epidermal necrolysis: revisit-ing the tentative link between early apoptosis and late necrosis. Int J Mol Med 2007; 19: 3-10
174. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-1312
175. Paquet P, Pierard GE. Soluble fractions of tumor necrosis factor-a interleukin-6 and of their receptors in toxic epidermal necrolysis: a comparison with second-degree burns. Int J Mol Med 1998; 1: 458-462
176. Correia O, Delgado L, Barbosa IL, et al. Increased inter-leukin 10, tumor necrosis factor a, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 2002; 47: 58-62
177. Moncada S, Palmer RJ, Higgs EA. Nitric oxide: physiol-ogy, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-116
178. Lerner LH, Qureshii AA, Reddy BV, et al. Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome. J Invest Dermatol 2000; 114: 196-199
179. Kroncke KD, Fehsel K, Kolb-Bachofen V. Nitric oxide: cytotoxicity versus cytoprotection-how, why, when, and where? Nitric Oxide Biol Chem 1997; 1: 107-120
180. Williams GP, Mudhar HS, Leyland M. Early pathological features of the cornea in toxic epidermal necrolysis. Br J Ophthalmol 2007; 91: 1129-1132
181. Groves RW, Allen MH, Barker JNWN, et al. Tumor ne-crosis factor alpha is pro-inflammatory in normal skin and modulates cutaneous adhesion molecule expression. Br J Dermatol 1995; 132: 345-352
182. Kando S, Kooshesh F, Sauder D. Penetration of kerati-nocyte derived cytokines into basement membrane. J Cell Physiol 1997; 171: 190-195
183. Hermanns-Le T, Paquet P, Pierard-Franchimont C, et al. Regulatory function of factor XIIIa-positive dendrocytes in incipient toxic epidermal necrolysis and graft-versus-host reaction. Dermatology 1999; 198: 184-186
184. Miyauchi H, Hosokawa H, Akaeda T, et al. T-cell subsets in drug-induced toxic epidermal necrolysis. Arch Derma-tol 1991; 127: 851-855
185. Correia O, Delgado L, Ramos JP, et al. Cutaneous T cell recruitment in toxic epidermal necrolysis: further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993; 129: 466-468
186. Le Cleach L, Delaire S, Baumsell L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000; 119: 225-230
187. Leyva L, Torres MJ, Posadas S, et al. Anticonvulsant-induced toxic epidermal necrolysis: monitoring the im-munologic response. J Allergy Clin Immunol 2000; 105: 157-165
188. Mayorga C, Torres MJ, Corzo JL, et al. Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin. Ann Allergy Asthma Immunol 2003; 91: 86-91
189. Correia O, Delgado L, Roujeau JC, et al. Soluble inter-leukin 2 receptor and interleukin 1a in toxic epidermal necrolysis. Arch Dermatol 2002; 138: 29-32
190. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114: 1209-1215
191. Inachi S, Mizutani H, Shimizu M. Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 1997; 133: 845-849
192. Godfrey DI, MacDonald R, Kronenberg M, et al. NKT cells: what's in a name? Nature Rev Immunol 2004; 4: 213-216
193. Mingari MC, Ponte M, Bertone S, et al. HLA class I specific inhibitory receptors in human T lymphocytes interleukin 15 induced expression of CD94/NKG2A in superantigen or alloantigen-activated CD8+ T cells. Proc Natl Acad Sci USA 1998; 95: 1172-1177
194. Caproni M, Torchia D, Schincaglia E, et al. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Der-matol 2006; 154: 319-324 (Pubitemid 43382704)
195. Ettore A, Andreassi M, Anselmi C, et al. Involvement of oxidative stress in apoptosis induced by a mixture of iso-thiazolinones in normal human keratinocytes. J Invest Dermatol 2003; 121: 328-336
196. Armeni T, Battino M, Stronati A, et al. Total antioxidant capacity and nuclear DNA damage in keratinocytes after exposure to H2O Biol Chem 2001; 301: 1697-1705
197. Schmidt D, Kluge W. Fatal toxic epidermal necrolysis fol-lowing reexposure to phenytoin: a case report. Epilepsia 1983; 24: 440-443
198. Glasser D, Burroughs S. Valdecoxib-induced toxic epider-mal necrolysis in a patient allergic to sulfa drugs. Pharmacotherapy 2003; 23: 551-553
199. Huang LY, Liao WC, Chiou CC, et al. Fatal toxic epi-dermal necrolysis induced by carbamazepine treatment in a patient who previously had carbamazepine-induced Stevens-Johnson syndrome.J Formosan Med Assoc 2007; 106: 1032-1037
200. Pasricha J, Khaitan B, Shantharaman R, et al. Toxic epi-dermal necrolysis. Int J Dermatol 1996; 35: 523-527
201. Kauppinen K. Cutaneous reactions to drugs. Acta Derm Venereol 1972; 52: S1-82
202. Herndon D. Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 1995; 180: 340-342
203. Kelemen JJ, Cioffi W, McManus W, et al. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995; 180: 283-288
204. McGee T, Munster A. Toxic epidermal necrolysis syn-drome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 1998; 102: 1018-1022
205. Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epi-dermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323-327
206. Roujeau JC, Albengres E, Moritz S, et al. Lymphocyte transformation test in drug-induced toxic epidermal ne-crolysis. Int Arch All Appl Immunol 1985; 78: 22-24
207. Paquet P, Schaaf-Lafontaine N, Pierard GE. Toxic epider-mal necrolysis following clindamycin treatment. Br J Dermatol 1995; 132: 665-666
208. Halevy S, Livni T. The role of macrophage migration inhibition factor in toxic epidermal necrolysis. Int J Der-matol 1997; 36: 764-768
209. Kano Y, Hirahara K, Mitsuyama Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007; 62: 1439-1444
210. Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it in the French way. Lancet 1985; ii: 1056-1058
211. Paquet P, Jacob E, Damas P, et al. Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell's syndrome) after putative b-lactam cross-reactivity: case report and scrutiny of antibiotic imputability. Crit Care Med 2002; 30: 2580-2583
212. Windle EM. Immune modulating nutrition support for a patient with severe toxic epidermal necrolysis. J Hum Nutr Dietet 2005; 18: 311-314
213. Prendiville JS, Hebert AA, Greenwald MJ, et al. Manage-ment of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989; 115: 881-887
214. Sheridan RL, Weber JM, Schulz JT, et al. Management of severe toxic epidermal necrolysis in children. J Burn Care Rehabil 1999; 20: 497-500
215. Chave TA, Mortimer NJ, Seladden MJ, et al. Toxic epi-dermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153: 241-253
216. Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 1996; 22: 275-278
217. Heimbach D, Engrav L, Marvin J, et al. Toxic epidermal necrolysis: a step forward in treatment. JAMA 1987; 257: 2171-2175
218. Birchall N, Langdon R, Cuono C, et al. Toxic epidermal necrolysis: an approach to management using cryo-preserved allograft skin. J Am Acad Dermatol 1987; 16: 368-372
219. Pianigiani E, Lerardi F, Taddeuci P, et al. Skin allograft in the treatment of toxic epidermal necrolysis (TEN). Der-matol Surg 2002; 28: 1173-1176
220. Klein L, Mericka P, Strakova H, et al. Biological skin covers in treatment of two cases of the Lyell's syndrome. Ann Transplant 1997; 2: 45-48
221. Bradley T, Brown R, Kucan JO, et al. Toxic epidermal necrolysis: a review and report of the successful use of Biobrane for early wound coverage. Ann Plast Surg 1995; 35: 124-132
222. Arevalo JM, Lorente JA. Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis. J Burn Care Rehabil 1999; 20: 406-410
223. Bannasch H, Kontiny U, Kruger M, et al. A semi-synthetic bilaminar skin substitute used to treat pediatric full-body toxic epidermal necrolysis. Arch Dermatol 2004; 140: 160-162
224. Asz J, Asd D, Moushey R, et al. Treatment of toxic epi-dermal necrolysis in a pediatric patient with a nanocrys-talline silver dressing. J Ped Surg 2006; 41: 9-12
225. Imamura Y, Fujiwara S, Sato T, et al. Successful treatment of toxic epidermal necrolysis with calcium sodium alginate fiber. Int J Dermatol 1996; 35: 834-835
226. Huang SH, Wu SH, Sun IF, et al. Aquacel® Ag in the treatment of toxic epidermal necrolysis (TEN). Burns 2008; 34: 63-66
227. Ghislain PD, Roujeau JC. Treatment of severe drug reac-tions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002; 8: 5-15
228. Fumal I, Braham C, Paquet P, et al. The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof-to-concept study. Dermatology 2002; 204: S79-85
229. Timsit JF, Mion G, Le Gulluche Y, et al. Severe hypo-thermia occurring during the course of toxic epidermal necrolysis in patients treated with air-fluidized beds [letter]. Arch Dermatol 1991; 127: 739
230. John T, Foulks G, John M, et al. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. Ophthalmol 2002; 109: 351-360
231. Kobayashi A, Yoshita T, Sugiyama K, et al. Amniotic membrane transplantation in acute phase of toxic epidermal necrolysis with severe corneal involvement. Ophthalmology 2006; 113: 126-132
232. Tandon A, Cackett P, Mulvihill A, et al. Amniotic mem-brane grafting for conjunctival and lid surface disease in the acute phase of toxic epidermal necrolysis. J AAPOS 2007; 11: 612-613
233. Paquet P, Kaveri S, Jacob E, et al. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. Exp Dermatol 2006; 15: 381-386
234. Ito K, Hara H, Okada T, et al. Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: im-munohistochemical study of Fas and Fas-ligand expression. Clin Exp Dermatol 2004; 29: 679-680
235. French LE, Trent JT, Kerdel F. Use of intravenous im-munoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Im-munopharmacol 2006; 6: 543-549
236. Tristani-Firouzi P, Petersen MJ, Saffle JR, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002; 47: 548-552
237. Campione E, Clare Marulli G, Carrozzo AM, et al. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 2003; 83: 430-432
238. Metry D, Jung P, Levy M. Use of intravenous immuno-globulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics 2003; 112: 1430-1436
239. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Arch Dermatol 2003; 139: 26-32
240. Tan A, Thong BY, Yip L, et al. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol 2005; 32: 1-6 (Pubitemid 40313054)
241. Mittmann N, Chan B, Knowles S, et al. Intravenous im-munoglobulin use in patients with toxic epidermal necro-lysis and Stevens-Johnson syndrome. Am J Clin Dermatol 2006; 7: 359-368
242. Stella M, Clemente A, Bollero D, et al. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective study. Burns 2007; 33: 452-459
243. Bachot N, Revuz J, Roujeau JC. Intravenous immuno-globulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2003; 139: 33-36
244. Brown KM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004; 25: 81-88
245. Schortt R, Gomez M, Mittman N, et al. Intravenous im-munoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004; 25: 246-255
246. Bachot N, Roujeau JC. Intravenous immunoglobulin in the treatment of severe drug eruptions. Curr Opin Allergy Clin Immunol 2003; 3: 269-274 (Pubitemid 37010882)
247. Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIg): clinical experience to date. Drugs 2005; 65: 2085-2090
248. Yip LW, Thong BY, Tan AW, et al. High dose intravenous immunoglobulin in the treatment of toxic epidermal ne-crolysis: a study of ocular benefits. Eye 2005; 19: 846-853
249. Schneck J, Stat D, Fagot JP, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EUR SCAR study. J Am Acad Dermatol 2008; 58: 33-40
250. Kardaun S, Jonkman M. Dexamethasone pulse therapy for Steven-Johnson syndrome/toxic epidermal necrolysis. Acta Dermatol Venereol 2007; 87: 144-148
251. Engelhardt SL, Schurr MJ, Helgerson RB. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil 1997; 18: 520-524
252. Guibal F, Bastuji-Garin S, Chosidow O, et al. Character-istics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 1995; 131: 669-672
253. Criton S, Devi K, Sridevi PK, et al. Toxic epidermal necro-lysis: a retrospective study. Int J Dermatol 1997; 36: 923-925
254. Van der Meer JB, Schuttelaar ML, Toth GG, et al. Suc-cessful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to ox-azepam. Clin Exp Dermatol 2001; 26: 654-656
255. Tegelberg-Stassen M, Van Vloten WA, Baart de la Faille H. Management of non-staphylococcal toxic epidermal necrolysis: follow-up study of 16 case histories. Derma-tologica 1990; 180: 124-129
256. Stables GI, Lever RS. Toxic epidermal necrolysis and sys-temic corticosteroids. Br J Dermatol 1993; 128: 357-360
257. Paquet P, Pierard GE. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology 1999; 198: 198-202 (Pubitemid 29204617)
258. Danby FW. Ciclosporin use in toxic epidermal necrolysis. Br J Dermatol 2007; 156: 378-379
259. Renfro L, Grant-Kels J, Damon L. Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Der-matol 1989; 28: 441-444
260. Zaki I, Patel S, Reed R, et al. Toxic epidermal necrolysis associated with severe hypocalcaemia and treated with cyclosporin. Br J Dermatol 1995; 133: 337-338
261. Sullivan JR, Watson A. Lamotrigine-induced toxic epi-dermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Aust J Dermatol 1996; 37: 208-212
262. Szepietowki J, Wasik F, Szybejko-Machay G, et al. Toxic epidermal necrolysis successfully treated with cyclospor-ine: report of three cases. J Eur Acad Dermatol Venereol 1997; 9: 169-172
263. Parrett P, Rademaker M, Havill J, et al. Toxic epidermal necrolysis treated with cyclosporine and granulocyte colony stimulating factor. Clin Exp Dermatol 1997; 22: 146-147
264. Arevalo J, Lorente JA, Gonzalez-Herrada C, et al. Treat-ment of toxic epidermal necrolysis with cyclosporin A. J Trauma Inj Inf Crit Care 2000; 48: 473-478
265. Hashim N, Bandara SD, Tan E, et al. Early cyclosporine treatment of incipient toxic epidermal necrolysis induced by concomitant use of lamotrigine and sodium valproate. Ann Derm Venereol 2003; 84: 90-91
266. Paquet P, Arrese Estrada J, Pierard GE. Oral cyclosporin and alopecia areata. Dermatology 1992; 185: 314-315
267. Zakrzewski JL, Lentini G, Sach U, et al. Toxic epidermal necrolysis: differential diagnosis of an epidermolytic der-mopathy in a hematopoietic stem cell transplant recipient. Bone Marrow Transplant 2002; 30: 331-333
268. Fischer M, Fiedler E, Marsch WC, et al. Antitumour necrosis factor-a antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002; 146: 707-708
269. Hunger R, Hunziker T, Buettiker U, et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-a treatment. J Allergy Clin Immunol 2005; 116: 923-924
270. Al-Shouli S, Abouchala N, Bogusz M, et al. Toxic epi-dermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol 2005; 85: 534-535
271. Meiss F, Helmbold P, Meykadeh V, et al. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumor necrosis factor-a antibody infliximab: report of three cases. J Eur Acad Dermatol Venereol 2007; 21: 717-719
272. Famularo G, Di Dona B, Canzona F, et al. Etanercept for toxic epidermal necrolysis. Ann Pharmacotherapy 2007; 41: 1083-1084
273. Velez A, Moreno JC. Toxic epidermal necrolysis treated with N-acetylcysteine. J Am Acad Dermatol 2002; 46: 469-470
274. Redondo P, De Felipe I, De la Pena A, et al. Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis: treatment with N-acetylcysteine. Br J Dermatol 1997; 136: 633-634
275. Redondo P, Ruiz de Erenchun F, Iglesias ME, et al. Toxic epidermal necrolysis: treatment with pentoxifylline. Br J Dermatol 1994; 130: 688-689
276. Sanclemente G, De la Roche C, Escobar C, et al. Pentox-ifylline in toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 1998; 38: 873-874
277. Heng MCY, Allen SG. Efficacyof cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol 1991; 25: 778-786
278. Frangogiannis NG, Boridy F, Mazhar M, et al. Cyclo-phosphamide in the treatment of toxic epidermal necro-lysis. South Med J 1996; 89: 1001-1003
279. Goulden V, Goodfield MJD. Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis. Br J Dermatol 1996; 135: 305-306
280. Inamo Y, Okubo T, Wada M, et al. Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Int Arch Allergy Immunol 2002; 127: 89-94
281. Kamanabroo D, Schmitz-landgraf W, Czarnetzki B. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985; 121: 1548-1549
282. Chaidemenos G, Chrysonallis F, Sambolos K, et al. Plas-mapheresis in toxic epidermal necrolysis. Int J Dermatol 1997; 36: 218-221
283. Yamada H, Takamori K, Yaguchi H, et al. A study of the efficacy of plasmapheresis for the treatment ofdrug induced toxic epidermal necrolysis. Ther Apher 1998; 2: 153-156
284. Egan CA, Grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999; 40: 458-461
285. Nomura T, Abe R, Fujimoto K, et al. Plasma exchange; a promising treatment for toxic epidermal necrolysis with AIDS. AIDS 2004; 18: 2446-2448
286. Lissia M, Figus A, Rubino C. Intravenous immunoglo-bulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg 2005; 58: 504-510
287. Reeves JH, Butt WW, Shann F, et al. Continuous plas-mafiltration in sepsis syndrome. Crit Care Med 1999; 27: 2096-2104
288. De Vriese AS, Colardyn FA, Philippe JJ, et al. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999; 10: 846-853
289. Furubacke A, Berlin G, Anderson C, et al. Lack of signifi-cant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis. Intensive Care Med 1999; 25: 1307-1310
290. Wolkenstein P, Latarjet P, Roujeau JC. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-1589